TITLE

Acarbose reduced the risk for cardiovascular disease and hypertension in impaired glucose tolerance

PUB. DATE
January 2004
SOURCE
ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p2
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article focuses on a study related to acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance, published in the 2003 issue of "Journal of the American Medical Association." Patients were allocated to acarbose, 100 mg 3 times daily with meals. Main outcome measures composite endpoint for major cardiovascular event, coronary heart disease, cardiovascular death, congestive heart failure, cerebrovascular events and peripheral vascular disease. The study found that acarbose reduced the risk for a major cardiovascular event and hypertension.
ACCESSION #
12104524

 

Related Articles

  • Acarbose reduced the risk for cardiovascular disease and hypertension in impaired glucose tolerance: COMMENTARY. Hackam, Daniel G. // ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p2 

    This article focuses on a study related to acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance (IGT), published in the 2003 issue of "Journal of the American Medical Association." IGT is a key phase in the development of type 2...

  • Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data T. Kaiser et al.: Does Acarbose prevent diabetes and cardiac events? Kaiser, T.; Sawicki, P. T. // Diabetologia;Mar2004, Vol. 47 Issue 3, p575 

    Introduction. Cardiovascular morbidity and mortality is a major and still unresolved threat to patients with reduced glucose tolerance and Type 2 diabetes mellitus. In epidemiological studies, in non-diabetic subjects, post-prandial glycaemia is positively associated with the risk of diabetes,...

  • Postprandial hypotension treated with acarbose in a patient with type 1 diabetes mellitus. Maule, Simona; Tredici, Mirko; Dematteis, Antonio; Matteoda, Cristina; Chiandussi, Livio // Clinical Autonomic Research;Dec2004, Vol. 14 Issue 6, p405 

    Treatment of postprandial hypotension (PPH) is often unsuccessful. We report a case of a type 1 diabetic patient suffering from severely symptomatic PPH. The patient was treated with acarbose and showed definite improvement of both glycemic control and PPH.

  • On the potential of acarbose to reduce cardiovascular disease. Standl, Eberhard; Theodorakis, Michael J.; Erbach, Michael; Schnell, Oliver; Tuomilehto, Jaakko // Cardiovascular Diabetology;2014, Vol. 13 Issue 1, p1 

    In the emerging landscape of cardiovascular (CV) outcome trials evaluating the effects of blood glucose lowering drugs in individuals with type 2 diabetes, it is becoming increasingly apparent that since the promising signals coming from the United Kingdom Prospective Diabetes Study (UKPDS) no...

  • Clinical Utility of Acarbose, an α-Glucosidase Inhibitor in Cardiometabolic Disorders. Yamagishi, Sho-ichi; Matsui, Takanori; Ueda, Seiji; Fukami, Kei; Okuda, Seiya // Current Drug Metabolism;Feb2009, Vol. 10 Issue 2, p159 

    Diabetes is associated with an increase risk for cardiovascular disease (CVD). Recently, macrovascular complications of diabetes have been shown to start before the development of diabetes. Indeed, several clinical studies have confirmed the increased risk of CVD in patients with impaired...

  • Evaluation of the Potential Clinical and Economic Effects of Bodyweight Stabilisation with Acarbose in Patients with Type 2 Diabetes Mellitus: A Decision-Analytical Approach. Banz, K.; Dinkel, R.; Hanefeld, M.; Schwanebeck, U. // PharmacoEconomics;1998, Vol. 13 Issue 4, p449 

    Bodyweight is an acknowledged independent risk factor for coronary heart disease (CHD). The present model analysis was undertaken to investigate the clinical and economic impact of bodyweight gain in patients with type 2 (non-insulin-dependent) diabetes mellitus and its effects on the...

  • Effect of Acarbose on the Bioavailability and Pharmacokinetics of Metronidazole in Healthy and Diabetic Subjects. Hussain, Saad A.; Kurji, Haydar A. H.; Ghareeb, Mowafaq M.; Abdulrazzaq, Munaf H. // British Journal of Pharmaceutical Research;2012, Vol. 2 Issue 1, p41 

    Although drug interactions with Acarbose are uncommon, there is a possibility for interference with the pharmacokinetic behaviors of concomitantly administered drugs. The present study was designed to evaluate the possible drug interactions between Acarbose and orally administered MTZ. Twelve...

  • Formulation and evaluation of matrix tablets of acarbose. Kumar, Ganesh; Juyal, V.; Badoni, P. P. // Drug Invention Today;May2010, Vol. 2 Issue 5, p264 

    Monolithic matrix tablet of Acarbose were formulated as controlled release tablets employing Hydroxypropyl methylcellulose and Eudragit in different concentration and combination, and sustained release behavior of the fabricated tablets were investigated. controlled released matrix tablets...

  • acarbose.  // Davis's Drug Guide for Nurses, 10th edition;2007, p82 

    The article presents a nursing guide for the antidiabetic acarbose. The drug is used for the management of type 1 diabetes in conjunction with dietary therapy. It explains the pharmacokinetics, contraindications, precautions, adverse reactions and side effects of the drug. Its nursing...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics